• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    4/25/24 12:31:09 PM ET
    $ACON
    $AHG
    $AONC
    $BACK
    Medical Specialities
    Health Care
    Real Estate
    Real Estate
    Get the next $ACON alert in real time by email

    Gainers

    • Aclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million.
    • Processa Pharma (NASDAQ:PCSA) stock moved upwards by 43.18% to $2.32. The market value of their outstanding shares is at $6.6 million.
    • Akso Health Group (NASDAQ:AHG) shares moved upwards by 29.87% to $1.0. The market value of their outstanding shares is at $109.5 million.
    • Eyenovia (NASDAQ:EYEN) shares increased by 22.87% to $0.72. The company's market cap stands at $33.9 million.
    • Predictive Oncology (NASDAQ:POAI) stock increased by 21.64% to $1.63. The company's market cap stands at $6.6 million.
    • IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 18.93% to $4.14. The market value of their outstanding shares is at $4.7 million.

    Losers

    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock declined by 33.1% to $1.54 during Thursday's regular session. The market value of their outstanding shares is at $2.0 million.
    • Organogenesis Hldgs (NASDAQ:ORGO) stock decreased by 22.32% to $2.31. The market value of their outstanding shares is at $305.4 million.
    • Xylo Technologies (NASDAQ:XYLO) shares decreased by 16.35% to $1.74. The market value of their outstanding shares is at $3.2 million.
    • Protagenic Therapeutics (NASDAQ:PTIX) stock declined by 14.31% to $1.4. The market value of their outstanding shares is at $6.2 million.
    • American Oncology Network (NASDAQ:AONC) shares fell 14.14% to $3.95. The company's market cap stands at $41.8 million.
    • INVO Bioscience (NASDAQ:INVO) shares decreased by 13.68% to $1.01. The market value of their outstanding shares is at $2.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AHG
    $AONC
    $BACK

    CompanyDatePrice TargetRatingAnalyst
    Eyenovia Inc.
    $EYEN
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    Predictive Oncology Inc.
    $POAI
    8/19/2024$3.00Buy
    H.C. Wainwright
    Organogenesis Holdings Inc.
    $ORGO
    6/28/2024$5.00Buy
    Lake Street
    Processa Pharmaceuticals Inc.
    $PCSA
    4/25/2024$8.00Buy
    H.C. Wainwright
    Organogenesis Holdings Inc.
    $ORGO
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    Organogenesis Holdings Inc.
    $ORGO
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    Organogenesis Holdings Inc.
    $ORGO
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    Organogenesis Holdings Inc.
    $ORGO
    11/10/2022Buy → Neutral
    BTIG Research
    More analyst ratings

    $ACON
    $AHG
    $AONC
    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m. Eastern Time on February 26th to discuss the results of the quarter and the fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live w

    2/19/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclarion Publishes 2026 Shareholder Letter from the Chairman

    Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected initia

    2/5/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 700 shares, decreasing direct ownership by 0.25% to 275,524 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/3/26 4:55:55 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Admin. and Legal Officer Freedman Lori was granted 245,905 shares and covered exercise/tax liability with 14,267 shares, increasing direct ownership by 29% to 1,023,355 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    2/20/26 5:29:07 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vice President, Strategy Cavorsi Robert was granted 110,040 shares and covered exercise/tax liability with 5,432 shares, increasing direct ownership by 61% to 276,115 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    2/20/26 5:28:53 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    SEC Filings

    View All

    Protagenic Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

    3/2/26 9:27:00 PM ET
    $PTIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/27/26 4:00:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Organogenesis Holdings Inc.

    10-K - Organogenesis Holdings Inc. (0001661181) (Filer)

    2/26/26 4:15:33 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MYDCOMBI issued to EYENOVIA INC.

    Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/8/23 1:05:04 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eyenovia downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

    11/18/24 7:44:30 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

    H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

    8/19/24 6:55:24 AM ET
    $POAI
    Industrial Specialties
    Health Care

    Lake Street initiated coverage on Organogenesis with a new price target

    Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00

    6/28/24 8:20:16 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    6/6/25 5:44:18 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

    Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announc

    11/5/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m. Eastern Time on February 26th to discuss the results of the quarter and the fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live w

    2/19/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

    PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo

    11/14/25 5:12:46 PM ET
    $POAI
    Industrial Specialties
    Health Care

    $ACON
    $AHG
    $AONC
    $BACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

    SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 8:09:56 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care